TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Cervical Ripening in Postmenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 45-80yrs of age~* Postmenopausal (amenorrhea for greater than 1 year)~* May or may not be using hormone replacement therapy~* Scheduled or to be scheduled for hysteroscopy/resectoscopy procedures~Exclusion Criteria:~* Pregnant~* Known Cancer~* Known hypersensitivity to prostaglandins.~* Those who are breastfeeding

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): Group 1 will received 200ug of misoprostol, to be placed into the posterior vaginal fornix 12 hours and 2 hours before their scheduled surgery (a total of 400ug of misoprostol).
- Group 2 (Type: PLACEBO_COMPARATOR): Group 2 will received placebo (empty gelatin capsule), to be placed into the posterior vaginal fornix 12 hours and 2 hours before their scheduled surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Glenohumeral Re-centering During Closed Kinetic Chain for Shoulder Physiotherapy. A Prospective and Randomized Study.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Painful shoulder causes by tendinopathy of the rotator cuff (without full-thickness tear)~* Diagnosis based on a MRI (dating less than 6 months)~Exclusion Criteria:~* Tendinopathy of the rotator cuff with full-thickness tear~* Stiffness of the shoulder (loss of more than 20° in passive external rotation or passive forward elevation)~* Previous shoulder surgery (less than 12 months)~* Previous subacromial injection (less than 6 months)~* Context of worker's compensation claims

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- experimental group (Type: EXPERIMENTAL): Dynamic Humeral Centering
- control group (Type: ACTIVE_COMPARATOR): Conventional physiotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Nordic-Baltic Coronary Revascularization Study in Patients With Proximal Left Descending Coronary Artery (LAD) Lesion.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Heart Team decision on treatment~1-VD patients with stable coronary artery disease or stabilized unstable angina pectoris/NSTEMI or silent ischemia Proximal LAD (pLAD) stenosis (\>90% by visual assessment or FFR \<80% The lesion may be treated by both PCI and surgery~Exclusion Criteria:~ST-elevation myocardial infarction within 24 hours. Expected survival \<1 year, because of high age or severe cardiac or non-cardiac disease.~Significant LM disease. Earlier CABG. PCI within 3 months. Significant valvular heart disease. Renal failure on dialysis Earlier disabling stroke Relative or absolute contraindication to dual antiplatelet therapy. Allergy relevant to the study treatments. Age \< 18 years. Study required information and consent suboptimal or impossible.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Percutaneous coronary intervention (PCI) (Type: ACTIVE_COMPARATOR): Currently, percutaneous coronary intervention (PCI) using balloon and drug eluting stents is the treatment of choice for treatment of a proximal LAD lesion.
- Coronary artery bypass grafting (CABG) (Type: EXPERIMENTAL): Coronary artery bypass grafting is a well established treatment with documented excellent long-term results for the treatment of proximal LAD lesion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Triathlon® Partial Knee Replacement (PKR) Outcomes Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The subject is a male or non-pregnant female 21-75 years of age at the time of enrollment.~* The subject requires a primary cemented unicompartmental knee replacement.~* The subject has a diagnosis of osteoarthritis (OA) or posttraumatic arthritis (TA).~* The subject has clinically intact cruciate and collateral ligaments and no ligamentous instability is present.~* The subject has less than 10 degrees of flexion contracture and greater than 90 degrees of flexion.~* The subject's preoperative mechanical alignment is less than 15 degrees of varus and 15 degrees of valgus.~* The subject has signed the Institutional Review Board (IRB) approved study specific Informed Patient Consent Form.~* The subject is willing and able to comply with postoperative scheduled clinical and radiographic evaluations and rehabilitation.~Exclusion Criteria:~* The subject has inflammatory arthritis or avascular necrosis(AVN).~* The subject is obese, BMI \> 35.~* The subject has a history of total or unicompartmental (contralateral compartment and/or patellofemoral joint) reconstruction of the affected joint.~* The subject has a history of anterior cruciate ligament (ACL) reconstruction.~* The subject has had a high distal femoral, or proximal tibial osteotomy.~* The subject has a mental, neuromuscular or neurosensory disorder, which would create an unacceptable risk of prosthesis instability, prosthesis fixation failure, or complications in post-operative care and/or limit the ability to assess the performance of the device.~* The subject has a systemic or metabolic disorder leading to progressive bone deterioration that the surgeon feels would affect the overall outcome of the study.~* The subject is immunologically suppressed, or is receiving chronic steroids (\>30 days duration).~* The subject has a known sensitivity to device materials.~* The subject's bone stock is compromised by disease and/or infection which cannot provide adequate support and/or fixation to the prosthesis.~* The subject's bone stock is compromised by a prior implantation which cannot provide adequate support and/or fixation to the prosthesis.~* The subject has an active or suspected latent infection in or about the knee joint.~* The subject is a prisoner.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Triathlon PKR (Type: OTHER): All subjects enrolled will receive the Triathlon PKR device.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: In Vivo Raman Spectroscopy of Human Capillary Beds

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* adult stable on dialysis and able to consent~Exclusion Criteria:~* inability to acquire IVRS signal

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IVRS studied (Type: None): subjects will be monitored for changes in hematocrit based on results of in vivo raman spectroscopy scatter

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Magnetic Anastomosis Device Relief of Malignant Gastric Outlet Obstruction

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with unresectable malignancy with, or at risk of developing gastric outlet obstruction with GOOSS ≤ 2~* Karnofsky Performance Score ≥ 60~Exclusion Criteria:~* Patient is unable to understand and execute informed consent~* Age below 18 years~* Patients with any prior gastrointestinal surgery that significantly alters gastrojejunal anatomy~* Implanted cardiac pacemaker, defibrillator or ventricular assist device~* Requirement for chronic anticoagulation, or with uncorrectable coagulopathy~* Patients receiving chronic steroids or other drugs that may impair wound healing or formation of an intact anastomosis~* Simultaneously participating in another investigational drug or device~* Patients with suspicion of, or documented multiple small bowel strictures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): palliative treatment of gastric outlet obstruction

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study to Assess the Effects of a Novel Application of Averaged Volume Assured Pressure Support Ventilation (AVAPS-AE) Therapy on Re-hospitalization in Patients With Sleep-Disordered Breathing With Co-morbid COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Hospitalized patients who are at high risk for readmission who are at least 18 years of age.~2. Specifically patients with (a) admission diagnosis of COPD AND (b) either a prior non-elective hospitalization (One in the past 12 months) OR active smoker who are ready for discharge AND (c) are also found to have sleep-disordered breathing (AHI ≥ 10 per hour; \>3% oxygen desaturation for hypopneas) by overnight portable respiratory study prior to hospital discharge.~3. Bedside spirometry revealing evidence for obstructive lung disease (post-bronchodilator; GOLD stage II or greater (FEV1 \<70% predicted post BD).~4. No previous home Positive Airway Pressure (PAP) or Non- Invasive Ventilation (NIV) use within the past year~Exclusion Criteria:~1. Central sleep apnea (Central apnea index \>5 per hour; and/or \>50% are central apneas \& hypopneas)~2. Clinically unstable, i.e., Acute Respiratory Failure, hypotensive shock, uncontrolled cardiac ischemia or arrhythmias, requiring life support ventilation or as otherwise determined by the investigator~3. Participants with Stage III \& IV Chronic Heart Failure as defined by the New York Heart Association (NYHA) Classification~4. Known or expected contraindications for the use of non-invasive ventilation per the assessment of the investigator.~5. Lack of medical insurance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AVAPS-AE Non-invasive ventilation therapy (Type: EXPERIMENTAL): Participants will be initiated on AVAPS-AE therapy (intervention arm) for 60 days. AVAPS-AE is a mode of therapy (Philips Respironics Inc, Monroeville, Pa) with potential advantages over the currently established modes of non-invasive positive pressure ventilation (CPAP and bilevel therapy). This mode of therapy incorporates AVAPS (automated adjustable Inspiratory Positive Airway Pressure (IPAP) setting to maintain target ventilation with a settable rate of change), Auto Expiratory Positive Airway Pressure (EPAP) and Auto Back up Rate.
- Standard of Care Group (Type: NO_INTERVENTION): Evaluation and treatment of the participant's sleep disordered breathing will be per their participant's health care provider's usual care pathway.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Aprepitant and Granisetron for the Prophylaxis of Radiation Induced Nausea and Vomiting - A Pilot Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with bone metastases from any primary solid tumor site scheduled to receive a single 8 Gy fraction of palliative radiotherapy considered to be moderately emetogenic (an area of at least 80 cm2 in the anterior/posterior direction and located between the level of upper border of T11 and the lower border of L3) in the RRRP at Sunnybrook Odette Cancer Centre will be considered eligible.~Exclusion Criteria:~* Exclusion criteria include having nausea or vomiting 24hrs prior to radiation~* Having received or being scheduled to receive cranial radiation, moderately or highly emetogenic cytotoxic therapy 7 days prior to, during, or after radiation, receiving corticosteroids (except inhaled or topical), 5HT3 receptor antagonists or NK-1 antagonists or other antiemetic medication, being allergic to study medications, having a KPS\<40, being pregnant or of childbearing potential and not using contraceptive measures.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aprepitant and Granisetron (Type: EXPERIMENTAL): Patients will be given a single dose of Granisetron 2 mg orally and Aprepitant 125 mg on Day 0 (at least one hour before on the day of RT) followed by 80 mg of Aprepitant once daily in the mornings on Days 1 and 2 following the Palliative radiation therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Neuromuscular Plasticity in Response to Obesity: Effects of Mechanical Overload, Metabolic Disorders and Age

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Female or male subject, aged between 20 and 70 years old (inclusive terminals).~* Subject with a BMI greater than 30kg/m².~* Subject with a stable weight for at least 3 months before the start of the study.~* Subject capable and willing to comply with the protocol and willing to give informed consent in writing.~* Subject affiliated to a social security system.~Exclusion Criteria:~Subject with a medical or surgical history deemed by the investigator to be incompatible with the study.~* Subject with a medical contraindication to intense activity.~* Subject weighing more than 170kg, which may damage the dynamometer chair.~* Subject with a treatment that, in the investigator's opinion, may interfere with the evaluation of study criteria, period of exclusion from a previous clinical study.~* Subject who has received a total amount of compensation since the beginning of the calendar year, greater than 4500 euros (amount may change depending on the regulation).~* Subject with a linguistic or physiological disability to sign informed consent.~* Subject deprived of liberty by administrative of juridical decision, under guardianship or curatorship.~* Pregnant or breastfeeding women.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- YOMH (Type: EXPERIMENTAL): Young obese metabolically healthy Description: Aged from 20 to 40 years old and with a glycemia \< 1g/l and a triglyceridemia \< 1,5g/l.
- YOMD (Type: EXPERIMENTAL): Young obese with metabolic disorders~Description: Aged from 20 to 40 years old and with a glycemia \> 1g/l and a triglyceridemia \> 1,5g/l.
- MAOMH (Type: EXPERIMENTAL): Middle-Age obese metabolically healthy~Description: Aged from 40 to 50 years old and with a glycemia \< 1g/l and a triglyceridemia \< 1,5g/l.
- MAOMD (Type: EXPERIMENTAL): Middle-Age obese with metabolic disorders Description: Aged from 40 to 50 years old and with a glycemia \> 1g/l and a triglyceridemia \> 1,5g/l.
- EOMH (Type: EXPERIMENTAL): Elderly obese metabolically healthy~Description: Aged from 50 to 70 years old and with a glycemia \< 1g/l and a triglyceridemia \< 1,5g/l.
- EOMD (Type: EXPERIMENTAL): Elderly obese with metabolic disorders~Description: Aged from 50 to 70 years old and with a glycemia \> 1g/l and a triglyceridemia \> 1,5g/l.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Preoperative Boost Radiotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Women with a biopsy proven diagnosis of ductal carcinoma in situ or invasive carcinoma of the breast. Biopsy tissue (either slides or block) from outside institutions will be reviewed to confirm diagnosis.~2. Breast preservation candidates (no prior breast or nodal radiotherapy, no imaging evidence of multicentric disease preventing resection through a single incision, no pregnant women, and no comorbid conditions precluding surgery)~3. cTis-T3 cancer judged to benefit (by treating radiation oncologist) from a tumor bed boost~4. Women of child-bearing potential must consent to use adequate contraception during the course of the study: (1) surgical sterilization (such as a tubal ligation or hysterectomy), (2) approved hormonal contraceptives (such as birth control pills, patches, implants or injections), (3) barrier methods (such as a condom or diaphragm) used with a spermicide, or (4) an intrauterine device (IUD). Contraceptive measures such as Plan B (TM), sold for emergency use after unprotected sex, are not acceptable methods for routine use.~5. White blood cell (WBC) \> 3000, Hgb \> 10, platelets \>100000 within 30 days of consent~6. Eligible for contrasted magnetic resonance imaging( MRI) on initial evaluation with glomerular filtration rate (GFR) ≥ 60 ml/min. A diagnostic MRI ordered within 60 days of diagnosis will be considered an acceptable alternative and will not be repeated.~7. Outside breast imaging will be reviewed at Duke to confirm that findings are consistent with trial eligibility~Exclusion Criteria:~1. Breast implant in the breast to be treated (contralateral breast implant is acceptable)~2. Medical conditions that may increase risk for poor cosmetic outcome (i.e. Lupus, rheumatoid arthritis, scleroderma)~3. Subjects unable to receive study treatment planning secondary to body habitus or inability to lie flat on the stomach for at least 1 hour~4. Positive serum pregnancy test~5. Insufficient breast imaging to judge clinical stage~6. Subjects without placement of a biopsy clip at the diagnostic procedure who are unwilling to undergo clip placement.~7. Subjects in whom treatment planning constraints cannot be met

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Single arm 7 Gray (Gy) fraction of radiotherapy (Type: EXPERIMENTAL): All subjects will receive a single 7 Gy fraction of radiotherapy to the intact tumor prior to surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Oral Versus Intravenous Hydration to Prevent Contrast Induced Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients \> 18 years undergoing an elective procedure involving intravascular administration of iodinated contrast media~* high risk for the development of Contrast Induced Nephropathy (as defined by guideline criteria~Exclusion Criteria:~* Age \< 18.~* Low risk for the development of CIN, therefore no need for hydration~* Emergency contrast procedure.~* Overt signs of overhydration; orthopnea or pulmonal rales at the time of the first consult.~Double or triple diuretic use for pre-existing heart failure. Severe heart failure, in which case salt load is not safe (physician decision) Severe renal failure (CKD stage V eGFR \< 15ml/min/1.73m2) Multiple Myeloma. Repeated contrast exposure \< 2 weeks Unstable serum creatinine \> 25% change \< 6 weeks The inability to provide written informed consent. Participation in another intervention study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: sodium chloride tablets (Type: EXPERIMENTAL): Arm A: sodium chloride 1g/10kg of body weight /day per os on day -2 and -1 before contrast exposure. With a maximum dose of 10 gram sodium chloride a day.
- B: isotonic saline intravenously (Type: ACTIVE_COMPARATOR): Sodium chloride solution (isotonic saline (NaCl 0.9%) total 1000ml in 4 hrs or (in case of heart failure or severe renal failure) 12 hrs before and in 4 or in 12 hrs after contrast administration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues